Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
Moodys
Express Scripts
Baxter

Last Updated: August 15, 2022

Investigational Drug Information for ADX-10061


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug ADX-10061?

ADX-10061 is an investigational drug.

There have been 17 clinical trials for ADX-10061. The most recent clinical trial was a Phase 3 trial, which was initiated on May 1st 2015.

The most common disease conditions in clinical trials are Narcolepsy, Syndrome, and Sleepiness. The leading clinical trial sponsors are Aldeyra Therapeutics, Inc., Jazz Pharmaceuticals, and ORA, Inc.

There are two US patents protecting this investigational drug and one hundred and seven international patents.

Recent Clinical Trials for ADX-10061
TitleSponsorPhase
ADX-629 Therapy for Sjogren-Larsson SyndromeWilliam Rizzo, MDPhase 1/Phase 2
Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's Diseasepharmtrace klinische Entwicklung GmbHPhase 1
Proof-of-concept Study of New Imaging Diagnostic in Patients With Suspected Alzheimer's DiseaseAlzeca Biosciences, Inc.Phase 1

See all ADX-10061 clinical trials

Clinical Trial Summary for ADX-10061

Top disease conditions for ADX-10061
Top clinical trial sponsors for ADX-10061

See all ADX-10061 clinical trials

US Patents for ADX-10061

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
ADX-10061 See Plans and Pricing Pharmaceutical propylene glycol solvate compositions McNeil-PPC, Inc. (Skillman, NJ) See Plans and Pricing
ADX-10061 See Plans and Pricing Pharmaceutical co-crystal compositions University of South Florida (Tampa, FL) The Regents of the University of Michigan (Ann Arbor, MI) Transform Pharmaceuticals, Inc. (Lexington, MA) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for ADX-10061

Drugname Country Document Number Estimated Expiration Related US Patent
ADX-10061 Austria AT550022 2022-02-15 See Plans and Pricing
ADX-10061 Australia AU2003211021 2022-02-15 See Plans and Pricing
ADX-10061 Australia AU2003213719 2022-02-15 See Plans and Pricing
ADX-10061 Australia AU2003243354 2022-02-15 See Plans and Pricing
ADX-10061 Australia AU2003243699 2022-02-15 See Plans and Pricing
ADX-10061 Australia AU2003267231 2022-02-15 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Mallinckrodt
Merck
Moodys
Express Scripts
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.